Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel gene therapy approach shows promise

16.12.2002


Vanderbilt University Medical Center investigators are reporting success with a novel gene therapy approach. Working with cells grown in the laboratory, the group is the first to repair a defective gene and demonstrate that the resulting protein product is functional, said Dr. Alfred L. George Jr., senior author of a study published Dec. 15 in the Journal of Clinical Investigation.



Although use of the approach in patients is still years in the future, the findings are an important step in showing that a particular method of gene repair is possible, said George, director of Vanderbilt’s division of Genetic Medicine.

"We have very solid evidence that we can repair messenger RNA (the copy of DNA that is used to manufacture proteins), and that the repair results in a protein that has normalized function," he said. "That’s a good sign and makes us optimistic about moving forward with this type of gene therapy strategy."


Gene therapy is a phrase that describes many different modes of gene-based treatments. The most widely used strategy seeks to put normal copies of a gene into cells with a defective gene. An alternative approach targets a defective gene for repair, either of the DNA itself or of the messenger RNA copy of the gene -- the strategy favored by George’s group. Repairing messenger RNA offers advantages over other types of gene therapy, George said, because it works specifically in cells that have messenger RNA copies of the gene. Cells that are not actively using the targeted gene will not contain any messenger RNA copies to be repaired.

"We think this approach may have a niche. It could be useful for any inherited disease, but it may have a special ability to correct a problem in a dominant disorder, George said.

The RNA repair method studied by George and colleagues employs molecules called ribozymes -- repair machines that can be engineered to correct a defect in a selected messenger RNA. The current work targets for repair a mutation that causes myotonia congenita, an inherited muscle disease with symptoms including muscle stiffness. Because myotonia congenita is not a debilitating disease, gene therapy may not be appropriate for some patients, George said, but the disease serves as an excellent model for testing ribozymes as potential gene therapeutics.

"We know a great deal about myotonia congenita," George said. "We know about the genetics and the physiology, and we have cell culture and animal models. We have many experimental armaments to study the disease."

In addition, George said, myotonia congenita provides a good test case for more severe inherited muscle diseases, such as muscular dystrophy and related disorders.

Myotonia congenita is caused by mutations in chloride channels -- donut-like pores that allow chloride ions to pass across the cell membrane. Because chloride channels are important participants in the contraction-relaxation cycle of skeletal muscle, defects in these proteins affect muscle relaxation and cause muscle stiffness.

Over 80 different myotonia congenita-associated chloride channel mutations have been identified, George said. His team targeted one of these for repair, a mutation that George and colleagues first identified in a Pennsylvania dog named Sparky.

Dr. Christopher Rogers, a former graduate student in George’s laboratory, engineered ribozymes to correct the "Sparky" defect and then introduced the ribozymes into cells harboring the mutant chloride channels. He demonstrated that the ribozymes could indeed repair the messenger RNA for the defective channels and that the resulting repaired proteins had normal chloride channel function. The repair was not effective in all cells, George said, but in a small percentage of cells, chloride channel function was completely restored.

"We know now that the ribozyme method can work; it’s effective at producing a protein with completely normal function," George said. "It would be nice if we knew it worked in the dog, and that’s the next step."

The investigators will continue studies in cells to improve the efficiency of the method before they test it in a group of Sparky’s descendants -- a dog model of myotonia congenita.


Other contributors to the Journal of Clinical Investigation study include Drs. Carlos G. Vanoye and Bruce A. Sullenger. The work was supported by the National Institutes of Health and the Muscular Dystrophy Association.

Leigh MacMillan | EurekAlert!
Further information:
http://www.mc.vanderbilt.edu/reporter/

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>